Respiratory Infections News

COVID-19 vaccination provided strong and durable protection among children and adolescents during two strong waves of infections, according to real-world study findings reported in Annals of Internal Medicine.

In September 2021, the Biden administration introduced the American Pandemic Preparedness Plan, a proposal to transform the country’s capabilities to respond to future pandemics.

Researchers linked more than 1 million deaths in Africa in 2019 to antimicrobial resistance, more than half of which were linked to just four pathogens.

A second tuberculosis outbreak linked to a viable bone allograft product contaminated with Mycobacterium tuberculosis resulted in five more cases and two deaths, according to the outbreak investigation.

Maternal influenza vaccination during pregnancy was associated with reduced chances of influenza-associated ED visits or hospitalizations in infants aged younger than 6 months, according to a study published in JAMA Pediatrics.

Multiple prevention tools against respiratory syncytial virus in children became available in the United States this year.

The monoclonal antibody nirsevimab prevented hospitalizations for respiratory syncytial virus-associated disease among infants “in conditions that approximated real-world settings,” researchers wrote in The New England Journal of Medicine.

COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs.

New guidance was published in 2023 for STD prevention, diabetic foot infections, infective endocarditis and more.

SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies.